ABEX Pharmaceutica

What ABEX Pharmaceutica does

ABEX Pharmaceutica (Pty) Ltd is a privately-held, family-owned pharmaceutical company founded in 2006 by John Hallam and headquartered in Gqeberha (Port Elizabeth), South Africa, with additional offices in Pretoria, Cape Town, Sydney, and Dublin. The company operates as an integrated pharmaceutical development and commercialization platform managing the full value chain from regulatory dossier preparation and product sourcing through supply chain management, pharmacovigilance, and channel sales. Its portfolio comprises 100+ approved generic prescription medicines across therapeutic categories including Anti-Infective, Cardiovascular, CNS, Oncology, and Pain, alongside a branded OTC consumer health range (evaQwax, Tiger Balm, ColdGuard, Nasaleze, ColdZyme) and medical devices held under SAHPRA licensing.

Revenue is generated through a hybrid model combining B2B licensing and distribution partnerships with global pharmaceutical companies, direct B2C sales of OTC brands through South African pharmacy networks (notably Clicks Group/Unicorn), and royalty/licensing income from out-licensed assets such as Nebivolol and the biosimilar Enoxaparin. Go-to-market is partnership-led, leveraging strategic joint ventures in Australia/New Zealand and the UK/EU, with a professional services element including eCTD regulatory software solutions provided through a partnership with EXTEDO. Customers include pharmaceutical companies seeking market access in regulated markets, healthcare professionals prescribing generics, and end consumers of OTC products.

The company has achieved several regulatory firsts — including the first eCTD Marketing Authorization in South Africa (2014) and the first biosimilar Enoxaparin EU approval (2016) — and secured ISO 9001 and ISO 13485 certifications in 2024. Its 2024 acquisition of Unicorn Pharmaceuticals consolidated its South African distribution footprint. Ownership remains concentrated with the founding family, no external funding rounds are disclosed, and headcount is in the 11-50 range.

Name

ABEX Pharmaceutica

Legal name

Abex Pharmaceutica (Pty) Ltd

Website

https://abexpharm.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

ABEX Pharmaceutica is a privately-held South African pharmaceutical company founded in 2006 that develops, licenses, and distributes generic prescription medicines, OTC consumer health brands, and medical devices across Africa, Europe, Australasia, and Southeast Asia.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Generic pharmaceuticals
• Consumer health products
• Pharmaceutical distribution
• Regulatory affairs services
• Medical devices

Headquarters

HQ city

Port Elizabeth

HQ country

South Africa

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Prescription Medicines: Abex manages a strong portfolio of registered generic medicines, commercialised through attractive and flexible business-to-business models that offer partners excellent market access and long-term growth potential. The company holds diverse portfolios including first-to-market generics such as Quetiapine and Sildenafil.
2. Branded OTC Products: Well-recognised portfolio of branded over-the-counter products including Consumer Health brands like EVAQWAX, Tiger Balm, and ColdGuard that meet wide range of consumer health needs.
3. Medical Devices: Abex obtained Medical Device Establishment Licence from MCC in 2017 and commercializes medical devices including Nasaleze and ColdZyme.
4. Licensing and IP Commercialization: First MA registered (Nebivolol) licensed out in 2010; First biosimilar Enoxaparin approved in EU and licensed out in 2016. Early-stage asset IP investment and co-development projects.
5. Strategic Consulting Services: Signed strategic consulting deal with Clicks Group to establish Unicorn pharmacy brand; provides software solutions for eCTD and pharmacovigilance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels1 record

Core offering

ABEX Pharmaceutica develops, registers, and commercializes a portfolio of generic prescription medicines across multiple therapeutic categories, branded OTC consumer health products (evaQwax, Tiger Balm, ColdGuard, Nasaleze, ColdZyme), and medical devices. It manages the full pharmaceutical value chain including product sourcing, regulatory affairs, supply chain management, pharmacovigilance, and sales, serving both B2B pharmaceutical partners and direct B2C pharmacy channels across Europe, Africa, Australasia, and South East Asia.

Product overview

Abex Pharmaceutica offers a diversified pharmaceutical portfolio consisting of generic prescription medicines across multiple therapeutic categories (Anti-Infective, Musculo-skeletal, Cardio Vascular, Central Nervous System, Respiratory, Gastro-intestinal, Oncology, Dermatology, and Pain), branded innovative products, OTC consumer health brands (evaQwax, Tiger Balm, ColdGuard, Nasaleze, ColdZyme), and medical devices. The company operates both B2B and direct B2C commercial models, managing the entire value chain from product development and regulatory affairs to supply chain management and sales and marketing. Abex commercializes its own brands while also offering partnership models for global pharmaceutical companies seeking market access.

Differentiator

Problem solved

Functional benefit

Brands

• ABEX Consumer Division: Consumer health division established in 2017 focusing on OTC products and medical devices
• Unicorn

Products and services

• evaQwax Ear Spray Ear spray scientifically formulated to remove impacted earwax from the external ear canal or to help prevent excessive earwax build-up, sold to consumers through pharmacy retail channels.
• Tiger Balm Red Ointment Topical ointment containing natural camphor 11% w/w and levomenthol 10% w/w for temporary relief of muscular cramps and rheumatic pain, improving blood circulation in micro-vessels; targeted at consumers via pharmacy retail.
• Tiger Balm White Ointment Topical ointment containing natural camphor 11% w/w and levomenthol 8% w/w for temporary relief of mild nasal/chest congestion and rheumatic pain, improving blood circulation in micro-vessels; targeted at consumers via pharmacy retail.
• ColdGuard Oral Spray Oral spray that protects against viruses causing common cold, upper respiratory tract infections, and flu-like symptoms; also shortens duration and alleviates related symptoms including sore throat, sold to consumers via pharmacy retail.
• Nasaleze Nasal spray product commercialized under exclusive rights in South Africa through the ABEX Consumer Division, targeting consumers seeking cold and allergy nasal protection.
• ColdZyme Enzymatic cold and flu treatment commercialized through exclusive partnership with Enzymatica covering Australia and New Zealand markets, sold via pharmacy distribution.
• Generic Prescription Medicines Portfolio Portfolio of registered generic prescription medicines across therapeutic categories including Anti-Infective, Musculo-skeletal, Cardio Vascular, CNS, Respiratory, Gastro-intestinal, Oncology, Dermatology, and Pain, commercialized to B2B pharmaceutical partners.
• Branded Innovative Prescription Products Portfolio of innovative branded prescription medicines, including biosimilars, commercialized through flexible B2B business-to-business models offering partners market access and long-term growth potential.
• Medical Devices Portfolio Diverse portfolio of medical devices including diagnostic and therapeutic devices held under Abex's Medical Device Establishment Licence from SAHPRA, sold to healthcare professionals and consumers.
• NEXA Prescription product commercialized in South Africa through strategic collaboration with Pharma Dynamics, targeted at healthcare professionals for prescribing to patients.
• Licensing and IP Out-Licensing Services Out-licensing of registered Marketing Authorizations, including biosimilars and generics, to pharmaceutical partners for commercialization in target markets, generating licensing and royalty income.
• Strategic Consulting Services Strategic consulting services for pharmaceutical and healthcare clients, including brand establishment, regulatory software enablement, and pharmacovigilance support.

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered major and core.

• EnzymaticamajorOEM/ Whitelabel/ Licensing Partner · 1 January 2019Signed exclusive partnership with Enzymatica in 2019 for the commercialization of ColdZyme in Australia and New Zealand markets.
• Pharma DynamicsmajorStrategic or Co-development Partner · 1 January 2018Entered strategic collaboration with Pharma Dynamics in 2018 to commercialize NEXA in South Africa.
• UK/EU Joint VenturecoreStrategic or Co-development Partner · 1 January 2018Established strategic JV in UK in 2018 for pan-EU sales footprint and R&D cooperation. Opened office in Cyprus and United Kingdom in 2017.
• South East Asian Markets Joint VenturemajorChannel Partner/ Reseller/ Distributor · 1 January 2011Established JV trading partnership into certain South East Asian markets in 2011 for distribution and market access.
• EXTEDOcoreTechnology or Integration · 1 January 2010Established as professional partner of EXTEDO in 2010 to provide Software Solutions for eCTD (electronic Common Technical Document) and pharmacovigilance in South Africa.
• Australia/New Zealand Joint VenturecoreStrategic or Co-development Partner · 1 January 2010Incorporated strategic JV in Australia and New Zealand in 2010 and won first major tender bid overseas. Acquired operating company approved by TGA in Australia in 2018.
• Carecross HealthcoreStrategic or Co-development Partner · 1 January 2009Formed Nucare in partnership with Carecross Health in 2009 and developed first integrated e-scripting program in South Africa, pioneering electronic prescribing solutions.
• Clicks GroupcoreStrategic or Co-development Partner · 1 January 2008Signed strategic consulting deal with Clicks Group in 2008 to establish Unicorn pharmacy brand. Later signed Strategic Distribution Agreement with Clicks (Unicorn) Pharmacies in 2016. Abex acquired Unicorn Pharmaceuticals in 2024.
• Unicorn PharmaceuticalscoreOthersAbex acquired Unicorn Pharmaceuticals in 2024, consolidating its position in the South African pharmaceutical market.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Pharma Dynamics: South African-focused pharmaceutical company that commercializes generics and branded Rx/OTC products. Abex signed a 2018 strategic collaboration with Pharma Dynamics for NEXA in South Africa, making it a directly comparable commercial peer in the same SA market with overlapping therapeutic categories.
• Cipla: Indian-headquartered global pharmaceutical company with deep South African presence, a large generics portfolio, and active biosimilar and OTC consumer health businesses. Comparable in international licensing model, emerging-market focus, and breadth across generic Rx and OTC consumer health.
• Adcock Ingram: Major South African pharmaceutical company with prescription, OTC, consumer health, and hospital portfolios. Comparable mid-cap SA pharma peer with overlapping OTC consumer health offerings and similar reliance on partnership-driven distribution channels.
• Aspen Pharmacare: Largest pharmaceutical manufacturer and distributor in South Africa with diversified branded, generic, OTC, and biosimilar portfolios across multiple continents. Most analogous large-scale peer to Abex's South African roots, multi-region footprint, and mixed branded-generic-biosimilar strategy.
• Lupin Limited: Indian-headquartered specialty generics manufacturer with strong emerging-market presence and biosimilar pipeline. Comparable business model focused on first-to-market generics, biosimilars, and licensing/royalty monetization across regulated markets.

Emerging players

• Enzymatica: Swedish-listed developer of the ColdZyme enzymatic cold-protection product, with Abex as exclusive commercialization partner for Australia and New Zealand. Smaller emerging player in the same OTC cold/cough category where Abex competes with ColdGuard and Nasaleze.

Broad incumbents

• Stada Arzneimittel: European-headquartered specialty generics and consumer healthcare company with broad branded-generic portfolio across more than 30 markets. Relevant comparable given Abex's UK/EU JV footprint, biosimilar licensing experience, and OTC consumer health brand commercialization.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive biosimilar and OTC consumer health businesses. Indirect large-scale comparable on generic Rx, biosimilar licensing, and branded OTC dimensions of Abex's portfolio.
• Hikma Pharmaceuticals: Global specialty pharmaceutical company with branded generics, injectables, and biosimilars across MENA, Europe, and the US. Relevant comparator given Abex's multi-region generics and licensing approach, particularly in oncology and cardiovascular therapeutic categories.
• Aurobindo Pharma: Vertically integrated Indian generic and specialty pharma manufacturer with strong emerging-market and European presence. Comparable in scaling generics, biosimilars, and licensing across multiple regulated geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABEX Pharmaceutica